Ed is a partner in our Corporate team and dual-qualified in England and Wales and California. He advises clients on strategic buy and sell-side M&A transactions, venture capital and growth equity financings, joint ventures, and restructurings, particularly within the technology and life sciences sectors.
Ed has extensive experience structuring, negotiating, and executing complex domestic and cross-border matters, regularly working across the UK, Europe, Nordics, and North America.
Ed is noted as a 'Key Lawyer' for mid-market M&A deals by Legal 500 UK 2025 and praised by clients for providing "the most exceptional service … always [going] above and beyond".
We have advised a syndicate of leading global life sciences investors including Access Biotechnology, Canaan Partners and SR One on their landmark US$140 million series A investment in Draig Therapeutics.
Press release
by Ed Chapman and Jack Coventry
Advising on Draig Therapeutics' US$140 million series A financing
by multiple authors
Advising Grant Thornton UAE on its business combination with Grant Thornton Advisors LLC
by multiple authors
by Kathleen Munstermann-Senff, LL.M. (Medical Law) and Dr. Martin Jäger
by Irina Rebin
by Dr. Julia Freifrau von Imhoff and Dr. Christian Frank, Licencié en droit (Paris II / Panthéon-Assas)
by Irina Rebin
by multiple authors
by multiple authors
by multiple authors